Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib

被引：0
|
作者：
Duan, J. C. [1 ]
机构：
[1] Canc Hosp Chinese Acad Med Sci, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
NSCLC; Third Generation EGFR-TKI; Resistance Mechanism;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-29
引用
收藏
页码：S652 / S652
页数：1
相关论文
共 50 条
  • [31] Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
    Vergnenegre, Alain
    Massuti, Bartomeu
    de Marinis, Filippo
    Carcereny, Enric
    Felip, Enriqueta
    Do, Pascal
    Miguel Sanchez, Jose
    Paz-Arez, Luis
    Chouaid, Christos
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 801 - 807
  • [32] The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis
    Yan, Han
    Li, Huihui
    Li, Qin
    Zhao, Pengfei
    Wang, Wei
    Cao, Bangwei
    PLOS ONE, 2015, 10 (08):
  • [33] Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Lim, Sun Min
    Lee, Jii Bum
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 376 - 379
  • [34] Gefitinib in First-Line Treatment of Caucasian Patients with NSCLC and EGFR Mutations in Exons 19 or 21
    Skrickova, Jana
    Hejduk, Karel
    Bortlicek, Zbynek
    Pesek, Milos
    Kolek, Viterslav
    Koubkova, Leona
    Grygarkova, Ivona
    Cernovska, Marketa
    Havel, Libor
    Tomiskova, Marcela
    Zemanova, Milada
    Roubec, Jaromir
    Sixtova, Dimka
    Coupkova, Helena
    Satankova, Monika
    Benejova, Andrea
    Hrnciarik, Michal
    Marel, Miloslav
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1240 - S1241
  • [35] Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Chen, Lanyi Nora
    Lee, Alexandria T. M.
    Nagasaka, Misako
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 380 - 384
  • [36] A Multicentre, Real-World Observational Study of First-Line Osimertinib and Post Progression Patterns in EGFR Positive NSCLC (Reiwa Study)
    Watanabe, K.
    Hosomi, Y.
    Naoki, K.
    Kato, T.
    Tsukita, Y.
    Matsumoto, H.
    Yoh, K.
    Fujisaka, Y.
    Takahashi, S.
    Takata, S.
    Usui, K.
    Kishi, K.
    Naka, G.
    Tamano, S.
    Uemura, K.
    Kunitoh, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S341 - S342
  • [37] Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
    Yang, J. C-H.
    Wang, M.
    Chiu, C-H.
    Hsu, P-C.
    Mitchell, P.
    Chang, C. L.
    Kim, T. M.
    John, T.
    Greillier, L.
    Bazhenova, L.
    Carcereny, E.
    Spira, A. I.
    Shim, B.
    Lee, K. H.
    Cobo Dols, M.
    Ghiringhelli, F.
    Yip, C. W.
    Xiong, J.
    Janne, P. A.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2023, 34
  • [38] Impact of the first-line treatment on the clinical course in Japanese NSCLC patients with EGFR mutations.
    Sakamori, Yuichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
    Chihara, Yusuke
    Takeda, Takayuki
    Goto, Yasuhiro
    Nakamura, Yoichi
    Tsuchiya-Kawano, Yuko
    Nakao, Akira
    Onoi, Keisuke
    Hibino, Makoto
    Fukuda, Minoru
    Honda, Ryoichi
    Yamada, Takahiro
    Taniguchi, Ryusuke
    Sakamoto, Sinjiro
    Date, Koji
    Nagashima, Seiji
    Tanzawa, Shigeru
    Minato, Koichi
    Nakatani, Koichi
    Izumi, Miiru
    Shimose, Takayuki
    Kishimoto, Junji
    Uchino, Junji
    Takayama, Koichi
    ONCOLOGIST, 2022, 27 (11): : 903 - E834
  • [40] TARGETED THERAPIES Optimal first-line therapy for NSCLC with EGFR mutations
    Neal, Joel W.
    Sequist, Lecia V.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (02) : 70 - 71
12345